Watson's Gelnique cleared by FDA for overactive bladder

01/29/2009 | WebMD

The FDA approved Watson Pharmaceuticals' Gelnique to treat an overactive bladder. The gel is intended to avert adverse reactions linked to other versions of oxybutynin, the product's active ingredient. The company expects to launch Gelnique as a prescription medication in the second quarter of this year.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA
Assistant General Counsel, Regulatorya
Cardinal Health
Waukegan, IL
Chief Operating Officer
Health Plan of San Joaquin
French Camp , CA